Cardio Diagnostics Holdings, Inc. (CDIO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cardio Diagnostics Holdings, Inc.'s filing signal turned negative.

Cardio Diagnostics Holdings, Inc. is a medical technology company focused on developing and commercializing AI-driven multi-omics tests for cardiovascular disease. Leveraging its proprietary AI-driven Multi-Omics EngineTM, the company aims to shift cardiovascular disease management from reactive treatment to proactive prevention and early detection. Its primary products, Epi+Gen CHDTM and PrecisionCHDTM, are blood tests designed to assess coronary heart disease risk and aid in diagnosis, respectively. Cardio also offers CardioInnovate360TM for biopharmaceutical research and HeartRiskTM, a cardiovascular disease risk intelligence platform. The company's go-to-market strategy emphasizes partnerships with healthcare providers, health systems, employers, and payors, with a focus on expanding market reach domestically and internationally.

Revenue is generated from the sale of its clinical blood tests, Epi+Gen CHDTM and PrecisionCHDTM, to provider organizations, patients, and employers. Pricing is negotiated based on organization type, volume commitments, and test utilization.